MUPIROCIN (mupirocin) by Teva is rna synthetase inhibitors [moa]. Approved for rna synthetase inhibitor antibacterial [epc]. First approved in 2003.
Drug data last refreshed 19h ago
RNA Synthetase Inhibitors
RNA Synthetase Inhibitor Antibacterial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
Impact of Mupirocin Decolonization on the Nasal Microbiome
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
Worked on MUPIROCIN at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.